Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of TIL-ACT + LDI in Advanced Solid Tumors
NCT03992326Phase 1Terminated
- Sponsor
- Lausanne University Hospital
- Start
- Sep 2019
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC101 TIL + pembrolizumab in solid tumor, sponsored by Lausanne University Hospital. Primary endpoints: Feasibility of TIL-ACT in combination with LDI - successful Rapid Expansion Protocol (REP) at Day 0, Feasibility of TIL-ACT in combination with LDI - successful infusion at Day 0 and 1 more. Started Sep 2019; status: terminated.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03992326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03992326.